← Back to search
REVAGENIX INC
SAN MATEO, CA, 94401
UnclaimedClaim this profile (free)
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | — | $26,944,787 | Jul 10, 2026 | Jul 1, 2020 – Aug 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | — | $28,167,401 | Jul 10, 2026 | Sep 22, 2022 – Apr 25, 2028 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.